Sanofi CFO Jerome Con­t­a­mine hits the ex­it; Strug­gling Fi­bro­cell trig­gers a strate­gic re­view

→ Pen­ny stock biotech Fi­bro­cell Sci­ence $FC­SC is wav­ing the white flag. Ex­ecs have be­gun a strate­gic re­view for the com­pa­ny, and every­thing is on the ta­ble. The gene ther­a­py com­pa­ny based in Ex­ton, PA is open to a sale or re­verse merg­er for any­one look­ing for a short cut to Nas­daq. It wouldn’t be ex­pen­sive. The biotech’s mar­ket cap has dwin­dled to $17 mil­lion.

Sanofi is prepar­ing for the re­tire­ment of  CFO Jerome Con­t­a­mine, who’s leav­ing the French drug­mak­er af­ter al­most 10 years in the role. Be­fore he leaves lat­er this year, the com­pa­ny says, Con­t­a­mine will help iden­ti­fy a suc­ces­sor and guide the tran­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.